CCM
AGN

Carderock Capital Management’s Allergan Inc AGN Stock Holding History

Carderock Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-105
Closed -$13K – 226
2014
Q1 		$13K Buy
+105
New +$12.8K 0.01% 192

Other funds holding AGN

PSCM
Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Carderock Capital Management's AGN Position: Q2 2014 in Review

Carderock Capital Management sold out of Allergan Inc (AGN) in Q2 2014, closing a stake of 105 shares — an estimated $13K sold.

Carderock Capital Management first reported a position in AGN in Q1 2014 and held it in 1 quarter. The position peaked at $13K in Q1 2014. 770 funds tracked by Wall St. Rank hold AGN as of Q2 2014.

  • Carderock Capital Management reported no remaining Allergan Inc position as of Q2 2014 after selling out during the quarter.
  • Carderock Capital Management sold 105 Allergan Inc shares in Q2 2014, an estimated $13K.
  • Carderock Capital Management first reported a position in Allergan Inc in Q1 2014 and held it in 1 quarter.
  • Carderock Capital Management's Allergan Inc position peaked at $13K in Q1 2014.
  • 770 funds tracked by Wall St. Rank held Allergan Inc as of Q2 2014.

Based on Carderock Capital Management's 13F filing for Q2 2014, filed 6 Aug 2014.